Keith G. Oldroyd, MD, MBChB, FRCP

Original Contribution

Improvement in Left Ventricular Function following Successful Rescue Percutaneous Coronary Intervention Is Independent of Time-t

08/01/2008

Colin Berry , MBChB, BSc, PhD, MRCP;

Keith G. Oldroyd , MD, MBChB, FRCP;

Kanarath P. Balachandran , MBBS, MD, MRCP;

Alastair C. Pell , MBChB, BSc, MD, MRCP;

Barry D. Vallance , MBChB;

Thrombolysis remains the most commonly used reperfusion therapy in acute myocardial infarction (AMI) in the United Kingdom, Europe and the developing world. Recent evidence suggests that thrombolysis may be equivalent to primary percutaneous...

Thrombolysis remains the most...

08/01/2008

Journal of Invasive Cardiology

Clinical Editor's Corner

Securing the Radial Sheath: An Update on a Pesky But Persistent Little Problem

11/03/2020

Peter J. Golden , RN;

Gurpreet S. Sandhu , MD, PhD;

Joe Moore ;

Larry S. Dean , MD, FACC, FAHA, FSCAI;

Karen Smith ;

Kirk N. Garratt , MD, MSc;

Emmanouil S. Brilakis , MD, PhD, FACC, FAHA, FESC, FSCAI;

Neal S. Kleiman , MD;

Morton J. Kern , MD, MSCAI, FACC, FAHA;

David J. Cohen , MD, MPH, MSc;

Jeffrey W. Moses , MD;

John Bittl , MD;

Mauricio G. Cohen , MD, FACC;

Mitchell W. Krucoff , MD;

Keith G. Oldroyd , MD, MBChB, FRCP;

Jeffrey Marshall ;

My daughter, at age 6, said to me many years ago when I was struggling with some vexing problem, “Dad, it’s not rocket surgery”. She meant to say rocket science, but we talked a lot of medicine then. Okay, I agree that securing the radial...

My daughter, at age 6, said to...

11/03/2020

Cath Lab Digest

Original Contribution

Clinical Outcomes in Patients Treated With Biodegradable-Polymer Biolimus-Eluting Stents and 6 Months of Dual-Antiplatelet Therapy: The French eBiomatrix 6-Month DAPT Registry

05/01/2022

Antoine Gommeaux , MD;

Vincent Malquarti , MD;

Denis Angoulvant , MD;

Clauset Cruchon , MD;

Keith G. Oldroyd , MD, MBChB, FRCP;

Christian Spaulding , MD;

Hakim Benamer , MD;

Thierry Lefèvre , MD;

Olivier Varenne , MD;

Janusz Lipiecki , MD;

Rajiv Rampat , MD;

Christophe Piot , MD;

François Brunelle , MD;

Rami el Mahmoud , MD;

Dual-antiplatelet treatment (DAPT) has conventionally been prescribed for 1 year after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation. Recent evidence suggests that a duration of only 6 months may be...

Dual-antiplatelet treatment...

05/01/2022

Journal of Invasive Cardiology